{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+C&page=8", "query": { "intervention": "Formulation C", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 321, "total_pages": 33, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+C&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+C&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T21:57:13.015Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01579084", "title": "Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rosacea", "Erythema" ], "interventions": [ { "name": "AGN-199201 Formulation A", "type": "DRUG" }, { "name": "AGN-199201 Formulation B", "type": "DRUG" }, { "name": "AGN-199201 Formulation C", "type": "DRUG" }, { "name": "AGN-199201 Vehicle", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2012-04", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2019-11-18", "last_synced_at": "2026-10-19T21:57:13.015Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01579084" }, { "nct_id": "NCT07680686", "title": "Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "Ubrogepant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 52, "start_date": "2026-07-14", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-19T21:57:13.015Z", "location_count": 1, "location_summary": "Grayslake, Illinois", "locations": [ { "city": "Grayslake", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07680686" }, { "nct_id": "NCT02495896", "title": "Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma", "Metastatic Pancreatic Adenocarcinoma", "Non-Resectable Cholangiocarcinoma", "Pancreatic Adenocarcinoma", "Recurrent Gallbladder Carcinoma", "Recurrent Non-Small Cell Lung Carcinoma", "Stage III Pancreatic Cancer", "Stage IIIA Gallbladder Cancer", "Stage IIIA Non-Small Cell Lung Cancer", "Stage IIIB Gallbladder Cancer", "Stage IIIB Non-Small Cell Lung Cancer", "Stage IV Gallbladder Cancer", "Stage IV Non-Small Cell Lung Cancer", "Stage IV Pancreatic Cancer", "Unresectable Gallbladder Carcinoma", "Unresectable Pancreatic Cancer" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Recombinant EphB4-HSA Fusion Protein", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2015-09-03", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-10-19T21:57:13.015Z", "location_count": 2, "location_summary": "Los Angeles, California • Newport Beach, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02495896" }, { "nct_id": "NCT01286454", "title": "This Is A Study Of Bioavailability And Food Effect For Fesoterodine.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency" ], "interventions": [ { "name": "fesoterodine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 20, "start_date": "2010-12", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2012-01-26", "last_synced_at": "2026-10-19T21:57:13.015Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01286454" }, { "nct_id": "NCT06144697", "title": "A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "BMS-986465", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "Famotidine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 267, "start_date": "2024-01-29", "completion_date": "2024-10-16", "has_results": false, "last_update_posted_date": "2025-02-06", "last_synced_at": "2026-10-19T21:57:13.015Z", "location_count": 2, "location_summary": "Anaheim, California • Austin, Texas", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06144697" }, { "nct_id": "NCT01387308", "title": "Study in Healthy Males to Assess the Bioavailability of 4 Different Fostamatinib Tablets", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Fostamatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 24, "start_date": "2011-08", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2011-10-28", "last_synced_at": "2026-10-19T21:57:13.015Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01387308" }, { "nct_id": "NCT04587713", "title": "Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Intestinal Disorder", "Bowel Diseases, Inflammatory" ], "interventions": [ { "name": "TD-1473 [Tablet A]", "type": "DRUG" }, { "name": "TD-1473 [Tablet B]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Theravance Biopharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 58, "start_date": "2020-10-16", "completion_date": "2020-12-27", "has_results": false, "last_update_posted_date": "2021-04-09", "last_synced_at": "2026-10-19T21:57:13.015Z", "location_count": 2, "location_summary": "Cypress, California • Lincoln, Nebraska", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04587713" }, { "nct_id": "NCT03078127", "title": "Researching the Effects of Airway Clearance Therapies in Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cystic Fibrosis", "Mucociliary Clearance Defect" ], "interventions": [ { "name": "Baseline (Huff-Cough alone)", "type": "OTHER" }, { "name": "Oscillatory Positive Expiatory Pressure Device", "type": "DEVICE" }, { "name": "Whole-Body Vibration Platform", "type": "DEVICE" }, { "name": "High Frequency Chest Wall Oscillatory Vest", "type": "DEVICE" } ], "intervention_types": [ "OTHER", "DEVICE" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2017-02-01", "completion_date": "2018-01-10", "has_results": true, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-10-19T21:57:13.015Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03078127" }, { "nct_id": "NCT07102316", "title": "A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "TPIP F2", "type": "DRUG" }, { "name": "TPIP F3", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Insmed Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 42, "start_date": "2025-08-19", "completion_date": "2025-11-03", "has_results": false, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-10-19T21:57:13.015Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07102316" }, { "nct_id": "NCT02214433", "title": "A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bacterial Infections" ], "interventions": [ { "name": "Placebo IV Solution", "type": "DRUG" }, { "name": "Debio 1450 IV Solution", "type": "DRUG" }, { "name": "Placebo Tablet or Capsule", "type": "DRUG" }, { "name": "Debio 1450 Tablet", "type": "DRUG" }, { "name": "Debio 1450 Capsule", "type": "DRUG" }, { "name": "Debio 1450 Oral Solution", "type": "DRUG" }, { "name": "Pantoprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 70, "start_date": "2014-08", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2015-02-25", "last_synced_at": "2026-10-19T21:57:13.015Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02214433" } ] }